Jpmorgan Chase & CO Graybug Vision, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.93 - $1.18 $6 - $8	7 New	7 $0
Q2 2022 Aug 11, 2022	SELL	$0.76 - $1.25 $408 - $672	-538 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.13 - $1.93 $607 - $1,038	538 New	538 $1,000
Q4 2021 Feb 10, 2022	SELL	$1.74 - $3.6 $187,511 - $387,954	-107,765 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.18 - $5.17 $342,692 - $557,145	107,765 New	107,765 $358,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.